Drug Search Results
More Filters [+]


Alternative Names: cycloserine, d-cycloserine, seromycin
Latest Update: 2024-02-15
Latest Update Note: Clinical Trial Update

Product Description

Cycloserine is a broad spectrum antibiotic used as a second line agent for treatment of drug resistant tuberculosis, always in combination with other antituberculosis agents. Cycloserine is appears to have little or no hepatotoxic potential, but it is usually used in combination with agents that are known to be hepatotoxic, and its role in the reported cases of liver injury with combination therapy cannot always be excluded. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cycloserine)

Mechanisms of Action: L-Alanine Racemase Inhibitor,D-Alanine Ligase Inhibitor,Cell Wall Synthesis Inhibitor,NMDA Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Canada | Chile | Colombia | Dominican Republic | Greece | Hong Kong | India | Ireland | Korea | Lithuania | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Philippines | Romania | Russia | Slovenia | South Africa | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cycloserine

Countries in Clinic: Australia

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Depressive Disorder, Major



Trial Status


Primary Completion Date

Probability of Success



Not yet recruiting

Depressive Disorder, Major





Depressive Disorder, Major


Recent News Events